neurodegenerative diseases - search results

Here, Ingrid R. Niesman, M.S., Ph.D. explains her research into a potential untapped model system, highlighting unmistakable similarities between human neurogenerative diseases and feline cognitive dysfunction syndrome.

Cecilia Van Cauwenberghe from Frost & Sullivan’s TechVision Group, provides an overview of Neurodegenerative Diseases.

Prof Dr Regina Fluhrer, from the University of Augsburg, explains how intramembrane proteases have been implicated in the emergence of neurodegenerative diseases.

Professor Dame Pamela Shaw explains how the National Institute for Health Research (NIHR) supports experimental medicine and translational research in neurodegenerative diseases.

The work of the EU Joint Programme – Neurodegenerative Disease Research (JPND) which aims to tackle the challenge of these diseases, in particular, Alzheimer’s, is discussed here

UCB's Duncan McHale outlines why reclassification might be a good idea to boost drug development for neurodegenerative diseases like Alzheimer's and Parkinson's Neurodegenerative diseases are a growing global challenge, as medical advances ensure more individuals live longer. By 2020 there will be more than 40 million people in the world...

Prof. Dr Axel Rominger from the Ludwig-Maximilian-University of Munich on how neurodegenerative diseases can be studied through PET imaging

Professor Duncan McHale, Head Global Exploratory Development at UCB discusses the challenge of developing drugs to treat neurodegenerative diseases

UCB's Duncan McHale outlines why reclassification might be a good idea to boost drug development for neurodegenerative diseases like Alzheimer's and Parkinson's Neurodegenerative diseases are a growing global challenge, as medical advances ensure more individuals live longer. By 2020 there will be more than 40 million people in the world...

Neurodegenerative diseases are a growing global challenge as medical advances ensures more individuals live longer. By 2020 there will be more than 40 million individuals in the world with Alzheimer’s disease and by 2040, without the development of truly disease modifying drugs this will be more than 80 million.

Professor Duncan McHale, Head Global Exploratory Development, UCB discusses reclassifying neurodegenerative diseases to enable drug development and to help patients... Neurodegenerative diseases are a growing global challenge as medical advances ensures more individuals live longer.  By 2020 there will be more than 40 million individuals in the world with Alzheimer’s disease and...

Paul A. Hyslop, from Arkley BioTek Indianapolis, details an ongoing specific research approach to identify, characterize, and validate physiologically relevant neuronal targets of H2O2 in designing therapeutics for neurodegenerative disease progression.

Researchers discuss how scientific innovations might influence the discovery of future tailor-made CB2R-based anti-inflammatory treatments.

Researchers give an update on clinical trials with CB2R agonists and their potential for the treatment of inflammatory diseases.

Tim Wooller, Principal – Industrial Design, Sector Lead Healthcare, PDD, explores how AI can help treat diseases such as cancer and stroke.

Expert scientists working on endocannabinoid system (ECS) trials explain how CB₂R can be used to treat inflammatory diseases.

Adonis Sfera and Zisis Kozlakidis provide recent insights into cellular and biological pathways from studies on communicable diseases.

According to NorthWestern Medicine, there are three different brain diseases that attack the language areas in the left hemisphere of the brain.

Jacqueline Hoogendam, JPND’s newly elected Vice-Chair and Executive Board member talks about JPND’s past and present strategies in its outreach campaign within and beyond Europe.

Professor of Neurology Thomas Gasser, JPND’s Scientific Advisory Board Chair and Director of the Department of Neurodegenerative Diseases, shares in an interview JPND’s innovative research and collaboration efforts in the universal race against Alzheimer’s and Parkinson’s diseases.